Ensho emerges with inflammatory disease portfolio from Eisai’s EA Pharma

Ensho Therapeutics has emerged with an inflammatory disease therapy portfolio from Eisai’s GI subsidiary EA Pharma, including a phase 2-ready clinical program in ulcerative colitis (UC).

The New Jersey-based biotech acquired a portfolio of oral α4β7 integrin inhibitors from Tokyo-based EA Pharma in a global licensing deal that was announced separately from the biotech’s unveiling. Ensho now has the right to develop, manufacture and commercialize the assets worldwide, excluding certain regions in Asia. Financial terms of the deal were not disclosed.  

The heart of the licensing pact is NSHO-101—also known as EA1080—a lymphocyte homing integrin α4β7 inhibitor designed to treat inflammatory bowel disease (IBD). Currently, there aren’t any marketed orally delivered α4β7 inhibitors available for IBD, though the mechanism has been validated by Entyvio, an approved monoclonal antibody targeting α4β7 for UC and Crohn’s disease. Both conditions are included under the IBD umbrella.

Ensho said it had nominated…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks